Neuropathix, Inc., a pain management life sciences company in Doylestown, has appointed pharmaceutical industry veteran Michael Ropacki, PhD, to its scientific advisory board.
Ropacki is a globally recognized executive with over 20 years’ clinical development experience. Among numerous professional affiliations, he is also a National Institute of Health advisor.
“I am extremely excited and grateful for the opportunity to join the Neuropathix Scientific Advisory Board,” Ropacki stated. “The company’s executive team [comprises] the highest-caliber scientists and executive leadership who are all devoted to developing socially responsible pain management and addiction-related novel therapies.”
He cited the current breadth of the opioid addiction crisis that Neuropathix has called him to help address:
- Over 100 million U.S. citizens struggle with chronic pain
- The domestic costs related to pain management are over $625 billion annually
- Almost two million opioid prescriptions written in the U.S. each year for pain
- Approximately 2.1 million Americans have an opioid-use disorder
“Joining the Neuropathix Scientific Advisory Board is an honor,” Ropacki concluded.
He is eager, he states, to “…help Neuropathix bring novel non-opioid therapeutic agents to market that treat chronic pain and help with opioid withdrawal and addiction.”
